Library — CHDR

Search

Filter

Safety, pharmacokinetics and exploratory pro-cognitive effects of HTL0018318, a selective M receptor agonist, in healthy younger adult and elderly subjects: a multiple ascending dose study.

Bakker C, Tasker T, Liptrot J, Hart EP, Klaassen ES, Doll RJ, Brown GA, Brown A, Congreve M, Weir M, Marshall FH, Cross DM, Groeneveld GJ, Nathan PJ

Alzheimer's research & therapy, 2021 Apr; 13(1):87

View publication
Spotlight Commentary: Importance of dose redefining in the process of drug repurposing.

Radanovic I, Likic R, Groeneveld GJ

British journal of clinical pharmacology, 2021 Apr; 87(4):1705-1707

View publication
A novel sustained-release cysteamine bitartrate formulation for the treatment of cystinosis: Pharmacokinetics and safety in healthy male volunteers.

Berends CL, Pagan L, van Esdonk MJ, Klarenbeek NB, Bergmann KR, Moerland M, van der Wel V, de Visser SJ, Büller H, de Loos F, de Vries WS, Waals H, de Leede LGJ, Burggraaf J, Kamerling IMC

Pharmacology research & perspectives, 2021 Apr; 9(2):e00739

View publication
Hydroxychloroquine Effects on TLR Signalling: Underexposed but Unneglectable in COVID-19

Aliede E. in ‘t Veld, Manon A. A. Jansen, Luuk C. A. Ciere and Matthijs Moerland

2021 Mar

View publication
The power of modelling pulsatile profiles.

van Esdonk MJ, Stevens J

Journal of pharmacokinetics and pharmacodynamics, 2021 Mar

View publication
A randomized single and multiple ascending dose study in healthy volunteers of LTI-291, a centrally penetrant glucocerebrosidase activator.

den Heijer JM, Kruithof AC, van Amerongen G, de Kam ML, Thijssen E, Grievink HW, Moerland M, Walker M, Been K, Skerlj R, Justman C, Dudgeon L, Lansbury P, Cullen VC, Hilt DC, Groeneveld GJ

British journal of clinical pharmacology, 2021 Feb

View publication
Predictive performance of parent-metabolite population pharmacokinetic models of (S)-ketamine in healthy volunteers.

Otto ME, Bergmann KR, Jacobs G, van Esdonk MJ

European journal of clinical pharmacology, 2021 Feb

View publication
A Phase 1, Randomized, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Pharmacodynamic Effects of VX-150, a highly selective NaV1.8 inhibitor, in Healthy Male Adults.

Hijma HJH, Siebenga PSP, de Kam MLM, Groeneveld GJGJ

Pain medicine (Malden, Mass.), 2021 Feb

View publication
Targeting for Success: Demonstrating Proof-of-Concept with Mechanistic Early Phase Clinical Pharmacology Studies for Disease-Modification in Neurodegenerative Disorders.

Vissers MFJM, Heuberger JAAC, Groeneveld GJ

International journal of molecular sciences, 2021 Feb

View publication

«
1
2
3
4
5
6
7
8
...
81
82
»